SCHEMBL19798458

SCHEMBL19798458

C[C@H](c1ccccc1)S(=O)(=O)NC12CC3CC(CC(C3)C1)C2

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 4/20 0.51
ALDH1A1 P00352 3/20 0.43
LMNA P02545 1/20 0.43
FAAH O00519 2/20 0.42
KMT2A Q03164 3/20 0.41
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
MAPK1 P28482 1/20 0.38
EPHX1 P07099 2/20 0.38
MEN1 O00255 1/20 0.37
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
TSHR P16473 1/20 0.36
ALOX12 P18054 1/20 0.36
HTT P42858 1/20 0.36
ATM Q13315 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19798456 1.00 EPHX2 (0.51) EPHX2ALDH1A1LMNAFAAHKMT2A
SCHEMBL19798454 1.00 EPHX2 (0.51) EPHX2ALDH1A1LMNAFAAHKMT2A
SCHEMBL19808243 0.86 EPHX2 (0.40) EPHX2ALDH1A1LMNAFAAHKMT2A
SCHEMBL20724768 0.86 EPHX2 (0.40) EPHX2ALDH1A1LMNAFAAHKMT2A
SCHEMBL19808239 0.86 EPHX2 (0.40) EPHX2ALDH1A1LMNAFAAHKMT2A
SCHEMBL19798452 0.75 GRIN2D (0.43) EPHX2ALDH1A1LMNAKMT2ANPC1
SCHEMBL812701 0.72 LMNA (0.71) EPHX2ALDH1A1LMNAFAAHKMT2A
SCHEMBL13189591 0.70 ALDH1A1 (0.44) ALDH1A1LMNAKMT2AKDM4EMAPT
SCHEMBL16503498 0.70 ALDH1A1 (0.44) ALDH1A1LMNAKMT2AKDM4EMAPT
SCHEMBL19808623 0.70 EPHX2 (0.50) EPHX2ALDH1A1LMNAFAAHKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10202388-B2 Fused-ring compounds, pharmaceutical composition and uses thereof Shanghai De Novo Pharmatech Co., Ltd. (CN) 2019-02-12 US disclosed
US-20180022752-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF Shanghai De Novo Pharmatech Co., Ltd. (CN) 2018-01-25 US disclosed
US-20180022752-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF Shanghai De Novo Pharmatech Co., Ltd. (CN) 2018-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10202388-B2 Fused-ring compounds, pharmaceutical composition and uses thereof IDO1, IDO2, TDO2 EPHX2 1124/4885ALDH1A1 2128/4885LMNA 4813/4885
US-20180022752-A1 FUSED-RING COMPOUNDS, PHARMACEUTICAL COMPOSITION AND USES THEREOF IDO1, IDO2, TDO2 EPHX2 1124/4885ALDH1A1 2128/4885LMNA 4813/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.